Genmab
GMAB
193 hedge funds and large institutions have $1.43B invested in Genmab in 2022 Q3 according to their latest regulatory filings, with 36 funds opening new positions, 79 increasing their positions, 60 reducing their positions, and 21 closing their positions.
71% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 21
32% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 60
24% more capital invested
Capital invested by funds: $1.15B → $1.43B (+$276M)
13.43% more ownership
Funds ownership: 54.07% → 67.5% (+13%)
7% more funds holding
Funds holding: 180 → 193 (+13)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
+$203M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
+$45.3M |
| 3 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$33.4M |
| 4 |
CCM
CAAS Capital Management
New York
|
+$12.3M |
| 5 |
Goldman Sachs
New York
|
+$8.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$15M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$9.87M |
| 3 |
BlackRock
New York
|
-$6.14M |
| 4 |
CFM
Capricorn Fund Managers
London,
United Kingdom
|
-$4.8M |
| 5 |
HJGA
Hardman Johnston Global Advisors
Stamford,
Connecticut
|
-$3.12M |
GMAB Hedge Fund Activity: Q3 2022 in Review
193 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Genmab (GMAB) for Q3 2022, worth a combined $1.43B — up 24% from $1.15B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new GMAB positions and 21 closed out — a net gain of 15 holders — while 79 added to existing stakes and 60 trimmed.
The largest buyer was AllianceBernstein, opening a new position worth an estimated $203M. The largest seller was Artisan Partners, cutting an estimated $15M.
- 193 institutional investors held Genmab (GMAB) as of Q3 2022, up from 180 in Q2 2022.
- Funds reported $1.43B of Genmab stock for Q3 2022, up 24% quarter-over-quarter.
- 36 funds opened new Genmab positions in Q3 2022 and 21 closed out, a net change of +15 holders.
- The largest Genmab buyer in Q3 2022 was AllianceBernstein, an estimated $203M added.
- The largest Genmab seller in Q3 2022 was Artisan Partners, an estimated $15M sold.
Based on aggregated 13F filings for Q3 2022.